- The dolastatins. 21. Synthesis, X-ray crystal structure, and molecular modeling of (6R)-isodolastatin 10
-
A practical synthesis of (6R)-isodolastatin 10 (1b) was devised, the X-ray crystal structure was determined, and this chiral isomer was found to have antineoplastic activity comparable to dolastatin 10 (1a).
- Pettit,Srirangam,Herald,Hamel
-
-
Read Online
- CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
-
The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
- -
-
Paragraph 0261; 0262
(2017/05/15)
-
- COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER
-
The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
- -
-
Page/Page column 110
(2017/05/17)
-
- A practical approach to asymmetric synthesis of dolastatin 10
-
Dolastatin 10, an antineoplastic agent for cancer chemotherapy, is a linear peptide possessing N,N-dimethyl Val-OH, l-valine, (3R,4S,5S)-dolaisoleucine, (2R,3R,4S)-dolaproine and (S)-dolaphenine. Our efficient synthesis includes the following three key features: (1) SmI2-induced cross-coupling was employed to couple aldehyde 11 with (S)-N-tert-butanesulfinyl imine 12 to generate the required stereocenters of Dap (7); (2) asymmetric addition of chiral N-sulfinyl imine 10 provided a straightforward approach to the synthesis of the protected Doe ((S,S)-8); (3) a practical method to the key subunit Val-Dil (24a) has been established as an alternative synthetic route for the synthesis of this challenging chemical structure.
- Zhou, Wen,Nie, Xiao-Di,Zhang, Yu,Si, Chang-Mei,Zhou, Zhu,Sun, Xun,Wei, Bang-Guo
-
p. 6119 - 6131
(2017/08/02)
-
- Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains
-
Synthetic analogues of the natural occurring dolastatin 10 are of great interest in cancer due to their potent in vitro activity and their uses as payloads in antibody drug conjugates (ADCs). Modification of the dolastatin 10 core scaffold has mainly focused on modifications of the P1, N-terminus, and P5, C-terminus, with minimal attention to the P2 subunit. In this paper we discuss the introduction of heteroatoms to the P2 side chain, which results in potent activity in vitro. The most active compounds contained azides in the P2 unit and required a phenylalanine-derived P5 subunit.
- Dugal-Tessier, Julien,Barnscher, Stuart D.,Kanai, Akira,Mendelsohn, Brian A.
-
supporting information
p. 2484 - 2491
(2017/09/27)
-
- CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
-
The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
- -
-
Page/Page column 38
(2016/11/17)
-
- IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
-
The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.
- -
-
Page/Page column 108
(2015/11/16)
-
- DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS
-
The present invention concerns a compound of following formula (I): where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: ■ a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ■ -(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ■ an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ■ a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
- -
-
Paragraph 31
(2014/11/13)
-
- DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS
-
The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
- -
-
Paragraph 24; 25
(2014/11/13)
-
- DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS
-
The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
- -
-
Paragraph 27; 28
(2014/11/13)
-
- CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
-
The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
- -
-
Page/Page column 123
(2013/06/05)
-
- Total synthesis of dolastatin 10 through ruthenium-catalyzed asymmetric hydrogenations
-
A total synthesis of dolastatin 10, a potent inhibitor of microtubule assembly, which displayed remarkable antineoplastic activity, is reported. Our synthetic approach was based upon ruthenium-promoted asymmetric hydrogenation of β-keto esters derived from (S)-Boc-proline and (S)-Boc-isoleucine for the construction of the two key units: (2R,3R)-Boc-dolaproine (Dap) and (3R)-Boc-dolaisoleucine (Dil).
- Mordant, Céline,Reymond, Sébastien,Tone, Hitoshi,Lavergne, Damien,Touati, Ridha,Ben Hassine, Bechir,Ratovelomanana-Vidal, Virginie,Genet, Jean-Pierre
-
p. 6115 - 6123
(2008/02/04)
-
- Compounds for treating tumors
-
The invention provides compounds of formula (I): wherein E, A, B′, R6, R7, R8, and R9 are defined in the specification which compounds exhibit anticancer activity and are useful for treating cancer.
- -
-
-
- Synthesis and antitumor activity of novel dolastatin 10 analogs
-
Dolastatin 10 (1) is a potent antineoplastic pentapeptide. Novel dolastatin 10 analogs each modified at one of the constituent amino acid derivatives, were synthesized and their antitumor activity was evaluated against P388 leukemia in mice. The structural requirements for antitumor activity are discussed. Some of the analogs, 31c, 35c, 38b, and 50c showed excellent activity in vivo. Highly active 50c, which lacks the thiazole group of 1, was selected for further development as an antitumor agent.
- Miyazaki,Kobayashi,Natsume,Gondo,Mikami,Sakakibara,Tsukagoshi
-
p. 1706 - 1718
(2007/10/03)
-
- The dolastatins. 22. Synthesis of Boc-dolaproinyl-dolaphenine and four related chiral isomers
-
Synthesis of the dolastatin 10 (1) dipeptide segment N-(tert-butoxycarbonyl)-dolaproinyl-dolaphenine (2, Boc-Dap-Doe) and four chiral isomers (3-5, 13) has been summarized. Formation of the amide bond was readily accomplished employing diethyl cyanophosph
- Pettit,Barkoczy,Srirangam,Singh,Herald,Williams,Kantoci,Hogan,Groy
-
p. 2935 - 2938
(2007/10/02)
-
- -
-
A stepwise synthesis of dolastatin 10 starting from the dolaphenine residue is described. The chiral dola isoleuine and dolaproine residues were obtained by 5-step procedures from the corresponding N-Boc amino acid. The key steps are respectively the NaBH4 reduction of an allylic ketone and the addition of an achiral Z-crotylboronate on the N-Boc-L-prolinal. Peptidic couplings were efficiently realised with reagents developed in the laboratory.
- Roux, Florence,Maugras, Isabelle,Poncet, Joel,Niel, Gilles,Jouin, Patrick
-
p. 5345 - 5360
(2007/10/02)
-
- Stereoselective Synthesis of Dolastatin 10 and Its Congeners
-
Efficient synthesis of dolastatin 10 (1), a potent antitumor peptide from a sea hare Dolabella auricularia, has been achieved in a stereoselective manner.Trisnordolastatin 10 (2) and its C9-epimer (3) have also been synthesized.
- Shioiri, Takayuki,Hayashi, Kyoko,Hamada, Yasumasa
-
p. 1913 - 1924
(2007/10/02)
-
- An expeditious synthesis of dolastatin 10
-
Total synthesis of dolastatin 10 (1) was completed by developing an efficient synthesis of two key amino acid components, Dil (6) and Dap (11), and subsequent stepwise coupling of five amino acid components from C-terminal Doe.
- Tomioka, Kiyoshi,Kanai, Motomu,Koga, Kenji
-
p. 2395 - 2398
(2007/10/02)
-
- Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare
-
The stereoselective and efficient synthetic route to dolastatin 10, an antineoplastic peptide from a sea hare, has been developed. Dolaproine, one of the unusual constituents, was prepared in a highly stereoselective manner by the Evans aldol methodology.
- Hamada, Yasumasa,Hayashi, Kyoko,Shioiri, Takayuki
-
p. 931 - 934
(2007/10/02)
-